Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (ORGO) is a leader in regenerative medicine, specializing in advanced wound care and surgical biologics. This page aggregates all official company announcements, press releases, and material developments for investors and industry observers.
Find updates on quarterly earnings, product innovations, regulatory milestones, and clinical trial progress. Our curated feed ensures timely access to information affecting ORGO's position in regenerative therapies and sports medicine markets.
Key areas include bioactive wound care solutions, FDA filings, partnership announcements, and manufacturing updates. All content is sourced directly from company communications to maintain accuracy and compliance.
Bookmark this page for easy access to Organogenesis' latest developments. Check back regularly for updates on their pioneering work in tissue repair technologies and healthcare market strategies.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced a new credit agreement with Silicon Valley Bank, introducing a $200 million credit facility. This includes a $75 million term loan and a $125 million revolving credit line, aimed at general corporate purposes and repaying an existing $100 million facility. Senior VP Henry Hagopian emphasized that this agreement will lower borrowing costs and support long-term growth. The partnership reflects the bank's commitment to the company’s innovation in advanced healing solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) plans to release its second-quarter fiscal year 2021 financial results on August 9, after market close. The management will host a conference call at 5:00 p.m. ET on the same day to discuss the results, followed by a Q&A session. Interested participants can join the call via phone or through a live webcast available on the company's investor relations website. A replay will be accessible for two weeks post-call. Organogenesis specializes in regenerative medicine focused on advanced wound care and surgical solutions.
Crocs Inc. (CROX) is set to replace Cantel Medical Corp. (CMD) in the S&P MidCap 400, effective June 2, 2021. Concurrently, Organogenesis Holdings Inc. (ORGO) will take Crocs' place in the S&P SmallCap 600. This change is part of an acquisition by STERIS plc of Cantel Medical, which is anticipated to conclude soon pending final conditions. This move reflects Crocs' growing presence in the market and the dynamics of index composition.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q1 2021, with net revenue of $102.6 million, a 66% increase from Q1 2020's $61.7 million. Advanced Wound Care products drove this growth, reaching $90.7 million (up 77%). The company achieved a net income of $9.9 million, a significant turnaround from the $16.3 million loss in the prior year. Operating income improved to $12.6 million. Looking ahead, net revenue guidance for 2021 is set between $438 million and $454 million, projecting a 29% to 34% increase year-over-year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) appointed Jon Giacomin to its Board of Directors, effective May 7, 2021, following Wayne Mackie's resignation on the same day. Giacomin brings nearly 30 years of healthcare experience, previously serving as CEO of U.S. Anesthesia Partners and Cardinal Health’s Medical Segment, which generated over $15 billion in revenue. This strategic leadership change aims to enhance the company’s growth potential as it continues to develop its regenerative medicine solutions in wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced its participation as a Platinum Sponsor at the upcoming 2021 Symposium on Advanced Wound Care Spring. The company will showcase its advanced wound care product lines, including PuraPly® AM and Apligraf®, with a focus on clinical evidence supporting their efficacy. On May 14, a presentation titled 'Clinical Evidence Outlines the Need for Early Advanced Standard of Care' will discuss a pooled analysis of 434 wounds. Other research highlights include podium and video presentations on the effectiveness of various wound care solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal year 2021 financial results after market close on May 10. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results and provide corporate updates. Interested participants can join by dialing 866-795-3142, with international callers using 409-937-8908, and using access code 9199306. A live webcast will also be available on their investor relations website, with a replay accessible for two weeks following the call.
Organogenesis Holdings (Nasdaq: ORGO) reported Q4 2020 net revenue of $106.8 million, a 43% increase YoY, driven by strong sales in Advanced Wound Care, which rose 48% to $93.6 million. Net income surged to $18.5 million from a loss of $4.4 million in Q4 2019. For FY 2020, total revenue reached $338.3 million, up 30%, with net income of $17.9 million. Looking ahead, the company expects FY 2021 revenue between $390 million and $405 million, reflecting a projected 15-20% growth.
Organogenesis Holdings (Nasdaq: ORGO) appointed David C. Francisco as Chief Financial Officer, effective February 15, 2021. Francisco, who has over 25 years of finance experience, previously held leadership roles at PerkinElmer, where he oversaw significant revenue growth. CEO Gary Gillheeney expressed optimism about Francisco's strategic insights, aiming to enhance operational performance and profitability amid growth opportunities. However, the company has faced substantial losses and competitive pressures, making its future profitability uncertain.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
